Royalty Pharma PLC
NASDAQ:RPRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Royalty Pharma PLC
NASDAQ:RPRX
|
US |
|
Amada Co Ltd
OTC:AMDWF
|
JP |
|
A
|
Atlantic Sapphire ASA
XMUN:4AS
|
NO |
|
I
|
Imax Corp
SWB:IMA
|
CA |
Wall St Price Targets
RPRX Price Targets Summary
Royalty Pharma PLC
According to Wall Street analysts, the average 1-year price target for RPRX is 58.381 USD with a low forecast of 46.46 USD and a high forecast of 69.3 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RPRX's stock price target?
Price Target
58.381
USD
According to Wall Street analysts, the average 1-year price target for RPRX is 58.381 USD with a low forecast of 46.46 USD and a high forecast of 69.3 USD.
What is the Revenue forecast for Royalty Pharma PLC?
Projected CAGR
18%
Over the last 7 years, the compound annual growth rate for Revenue has been 4%. The projected CAGR for the next 3 years is 18%.
What is the Operating Income forecast for Royalty Pharma PLC?
Projected CAGR
12%
Over the last 7 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 12%.
What is the Pre-Tax Income forecast for Royalty Pharma PLC?
Projected CAGR
37%
Over the last 7 years, the compound annual growth rate for Pre-Tax Income has been -2%. The projected CAGR for the next 3 years is 37%.
What is the Net Income forecast for Royalty Pharma PLC?
Projected CAGR
63%
Over the last 7 years, the compound annual growth rate for Net Income has been -8%. The projected CAGR for the next 3 years is 63%.
